Article

Acute respiratory tract infection: a practice examines its antibiotic prescribing habits.

Department of Family Medicine, Mayo Clinic, Scottsdale, AZ 85260, USA.
The Journal of family practice (Impact Factor: 0.67). 06/2012; 61(6):330-5.
Source: PubMed

ABSTRACT We wanted to better understand our practice behaviors by measuring antibiotic prescribing patterns for acute respiratory tract infections (ARTIs), which would perhaps help us delineate goals for quality improvement interventions. We determined (1) the distribution of ARTI final diagnoses in our practice, (2) the frequency and types of antibiotics prescribed, and (3) the factors associated with antibiotic prescribing for patients with ARTI.
We looked at office visits for adults with ARTI symptoms that occurred between December 14, 2009, and March 4, 2010. We compiled a convenience sample of 438 patient visits, collecting historical information, physical examination findings, diagnostic impressions, and treatment decisions.
Among the 438 patients, cough was the most common presenting complaint (58%). Acute sinusitis was the most frequently assigned final diagnosis (32%), followed by viral upper respiratory tract infection (29%), and acute bronchitis (24%). Sixty-nine percent of all ARTI patients (304/438) received antibiotic prescriptions, with macrolides being most commonly prescribed (167/304 [55%]). Prescribing antibiotics was associated with a complaint of sinus pain or shortness of breath, duration of illness ≥8 days, and specific abnormal physical exam findings. Prescribing rates did not vary based on patient age or presence of risk factors associated with complication. Variations in prescribing rates were noted between individual providers and groups of providers.
We found that we prescribed antibiotics at high rates. Diagnoses of acute sinusitis and bronchitis may have been overused as false justification for antibiotic therapy. We used broad-spectrum antibiotics frequently. We have identified several gaps between current and desired performance to address in practice-based quality improvement interventions.

0 0
 · 
0 Bookmarks
 · 
69 Views
  • [show abstract] [hide abstract]
    ABSTRACT: We investigated antimicrobial susceptibility and the molecular mechanism involved in conferring high-level macrolide resistance in 47 clinical isolates of Moraxella nonliquefaciens from Japan. Antimicrobial susceptibility was determined using the Etest and agar dilution methods. Thirty-two erythromycin-nonsusceptible strains were evaluated for the possibility of clonal spreading, using PFGE. To analyse the mechanism related to macrolide resistance, mutations in the 23S rRNA gene and the ribosomal proteins, and the presence of methylase genes were investigated by PCR and sequencing. The efflux system was examined using appropriate inhibitors. Penicillin, ampicillin, amoxicillin, cefixime, levofloxacin, and antimicrobials containing β-lactamase-inhibitors showed strong activities against 47 M. nonliquefaciens, of which 32 (68.1%) showed high-level MICs to macrolides (MIC ≥ 128 mg/L) and shared the A2058T mutation in the 23S rRNA gene. The geometric mean MIC to macrolides of A2058T-mutated strains was significantly higher than that of wild-type strains (P < 0.0001). Thirty-two isolates with high-level macrolide MICs clustered into 30 patterns on the basis of the PFGE dendrogram. In contrast, no common mutations of the ribosomal proteins, methylase genes, or overproduction of the efflux system were observed in A2058T-mutated strains. Moreover, of 47 M. nonliquefaciens strains, 43 (91.5%) were bro-1, and 4 (8.5%) were bro-2 positive. Our results suggested that most M. nonliquefaciens clinical isolates show a high-level macrolide resistance conferred by the A2058T mutation in the 23S rRNA gene. This study represents the first characterization of M. nonliquefaciens.
    Journal of Medical Microbiology 11/2013; · 2.30 Impact Factor